Trupanion, a leading pet medical insurance provider in North America, has opened nominations for its annual Veterinary Appreciation Day Awards. The company introduced a new award category this year—Veterinary Team of the Year—to recognize the collaborative efforts of entire clinic teams. The nomination period runs from April 16 to May 7, 2026, with voting from May 12-26 and winners announced on June 18, 2026.

Trupanion CFO Fawwad Qureshi sold his final 2,837 shares on February 27, 2026, completing a systematic divestment plan initiated in May 2025. The sale, executed under a pre-planned 10b5-1 trading plan for financial diversification, was not discretionary and should not be viewed as a negative signal about the company's prospects. This was the seventh and final transaction in a series of identical-sized sales scheduled in advance.

PRISM MarketView launched the PRISM PetCare Index to track publicly traded companies driving growth in the global pet care sector, projected to exceed $350 billion. The index includes companies advancing veterinary services, pet pharmaceuticals, insurance, diagnostics, and premium nutrition. Key companies highlighted include Elanco Animal Health, Chewy, and Trupanion, which are positioned to benefit from increasing consumer spending on pet healthcare, preventative services, and subscription-based offerings.

Chewy is a successful e-commerce pet retailer with over 130,000 products, but the article advises caution before investing. While the company showed 8.3% year-over-year revenue growth in Q3 2025 with improving profit margins, structural challenges persist. With net profit margins around 2% and the entire pet industry characterized by low margins, Chewy's growth prospects appear limited. The author recommends staying on the sidelines until profitability improves and valuation drops.

Trupanion will host a webinar on the evolving state of bird flu (H5N1) and its impact on pets, pet parents, and the veterinary community. The webinar will feature a panel of leading animal health experts and aims to equip veterinary professionals and pet parents with the latest information and practical guidance on avian flu in pets.

Trupanion, a leader in pet medical insurance, reported mixed Q4 2024 earnings. While revenue exceeded expectations, earnings per share (EPS) fell short. However, the company showed a significant turnaround, moving from a net loss to a net income of $1.7 million.

The article discusses three stocks - PureCycle Technologies (PCT), NuScale Power (SMR), and Trupanion (TRUP) - that have high short interest but are still trading near their 52-week highs, indicating a disconnect between bearish sentiment and stock performance.

Trupanion is launching a pet costume contest to spotlight adoptable pets and the shelters/rescues that care for them, with the goal of connecting these pets with potential families.

Four analysts have published ratings on Trupanion in the last three months, offering a range of perspectives. The average 12-month price target has increased by 8% to $33.75, with a high estimate of $49 and a low of $22. The analysts' ratings and price targets provide insights into Trupanion's market standing and performance.

The Accident and Health Insurance industry is expected to benefit from increased underwriting exposure and adoption of technology, despite ongoing pricing pressure and potential rise in claims frequency. Aflac, Unum Group, and Trupanion are highlighted as companies that should continue to perform well in this environment.

Trupanion (NASDAQ:TRUP) has been analyzed by 5 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 0 3 0 0 Last 30D 0 0 1 0 0 1M Ago 0 0 0 0 0 2M Ago 2 0 1 0 0 3M Ago 0 0 1 0 0 Analysts have set 12-month price targets for Trupanion, revealing an average target of $32.6, a high estimate of $49.00, and a low estimate of $22.00. This current average has increased by 3.82% from the previous average price target of $31.40. Deciphering Analyst Ratings: An In-Depth Analysis An in-depth analysis of recent analyst actions unveils how financial experts perceive Trupanion. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target John Barnidge Piper Sandler Raises Neutral $30.00 $22.00 Joshua Shanker B of A Securities Raises Buy $49.00 $35.00 Maria Ripps Canaccord Genuity Lowers Buy $34.00 $40.00 John Barnidge Piper Sandler Lowers Neutral $22.00 $28.00 John Barnidge Piper Sandler Lowers Neutral $28.00 $32.00 Key Insights: Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Trupanion. This information provides a snapshot of how analysts perceive the current state of the company. Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ...Full story available on Benzinga.com

SEATTLE, June 19, 2024 (GLOBE NEWSWIRE) -- Trupanion, Inc. (Nasdaq: TRUP), the leading provider of medical insurance for cats and dogs, will host its Annual Investor Day on Wednesday, September 18, 2024. This annual event is designed to be the best opportunity for Trupanion shareholders and guests to understand Trupanion’s achievements and challenges over the past year and its strategic vision going forward.